Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corfluvec Intranasal Vaccine for COVID-19 Prevention
NCT05696067Phase 2Completed
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Corfluvec in coronavirus disease 2019 (COVID-19). Started Sep 2022; status: completed.
02
Drugs
Corfluvec
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05696067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696067.